EN DE
Watch HAW PAR CORP LTD for free: we tell you when fair value or trend changes.
Data-driven stock valuation

HAW PAR CORP LTD (H02) fair value: what the stock is really worth

As of Nov 4, 2026: fair value (intrinsic value) of HAW PAR CORP LTD stock S$14.26, price S$12.79, upside +11.5%, quality 68 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SG1D25001158

HP HAW PAR CORP LTD logo Broad data Nov 1, 2026

HAW PAR CORP LTD

H02 · SG
Undervalued, but in a downtrend

The stock costs 10% less than our calculation considers fair.

Fair value 14.26 SGD · Undervalued (10%)
Quality 68/100
Highly profitable · 104.4% net margin (TTM)
Low debt
Generates free cash flow
Broad data
Mixed Growth (revenue 5y +15.7 %/yr in SGD)
3.1% dividend yield · Watch coverage
Mixed vs. peers (8/14)
Revenue last quarter 8% below a year ago.
Narrow moat 41/100 · thin data
Quality growth

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

17.81 SGD 7.26 SGD Fair Value 14.26 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.

How to read this chart

60‑month range 7.26 SGD – 17.81 SGD · fair‑value band 10.70 SGD – 21.82 SGD · the 12.79 SGD price screens below the 14.26 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 1, 2026.

Follow HAW PAR CORP in your weekly email

Every Wednesday you see whether HAW PAR CORP is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally.

Show moreShow less

It manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands; and invests in quoted securities. The company also owns and leases various investment properties.

In addition, it provides family and tourist oriented leisure activities primarily in the form of oceanariums. Further, the company is involved in the property development; and owning and letting properties; letting out of office spaces; and management support services.

Haw Par Corporation Limited was incorporated in 1969 and is based in Singapore.

Stock analysis

HAW PAR CORP LTD (H02) currently trades at 12.79 SGD, while our model-based Fair Value estimate is 14.26 SGD, implying the stock looks roughly 10% undervalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of 24.72 SGD per share, and 13 of the 26 models we run sit above the 12.79 SGD price.

Bear case: the Economic Profit group reads lowest at 6.44 SGD, and 13 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: 10.70 SGD (bear) to 21.82 SGD (bull), the price of 12.79 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2020: revenue and profit before it include the divested business. Growth is measured afresh from 2020.

HAW PAR CORP LTD reported revenue of 230M SGD in FY2025 versus 141M SGD in FY2021, a compound +13.0%/yr. Reported net income was 265M SGD in FY2025, compounding +24.6%/yr from FY2021.

Key figures

Market cap 2.8B SGD (≈ $2.2B) Mid · P/E ratio 12.3 · P/S ratio 12.9 · EPS (TTM) 1.04 SGD · Dividend yield 3.1% · Net margin 104% · Return on equity 5.2% · Return on assets (EBIT) 1.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 11%, H02 screens cheaper than that median.

Fair Value models

Bear 10.70 SGD Fair Value 14.26 SGD Bull 21.82 SGD
Price 12.79 SGD · Upside +11.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.5401 SGD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 6.86 SGD 9.79 SGD 15.15 SGD 80
Growth DCF 6.86 SGD 9.65 SGD 14.77 SGD 78
5Y EBITDA Exit 6.67 SGD 9.18 SGD 12.28 SGD 76
All 26 models by family
DCF Models
FCF DCF 6.86 SGD 9.79 SGD 15.15 SGD 80
Owner Earnings 20.00 SGD 34.00 SGD 59.60 SGD 74
5Y Revenue Exit 5.94 SGD 7.68 SGD 10.00 SGD 74
5Y EBITDA Exit 6.67 SGD 9.18 SGD 12.28 SGD 76
5Y P/E Exit 17.11 SGD 30.44 SGD 45.77 SGD 69
10Y Revenue Exit 6.13 SGD 7.91 SGD 10.56 SGD 68
10Y EBITDA Exit 6.71 SGD 9.03 SGD 12.50 SGD 69
10Y P/E Exit 13.81 SGD 25.01 SGD 41.10 SGD 62
Earnings-Based
Graham-Dodd 8.15 SGD 36.23 SGD 49.62 SGD 64
Lynch FV 9.40 SGD 13.43 SGD 17.46 SGD 61
PEG = 1.0 9.40 SGD 13.43 SGD 17.46 SGD 57
EPV 5.97 SGD 6.44 SGD 6.86 SGD 74
Dividend Discount
Gordon GGM 13.71 SGD 30.55 SGD 52.76 SGD 65
DDM Multi-Stage 13.71 SGD 24.72 SGD 31.74 SGD 66
Multiples
P/E Multiple 19.79 SGD 26.38 SGD 32.98 SGD 63
P/S Multiple 2.73 SGD 3.64 SGD 4.54 SGD 58
P/B Multiple 65.25 SGD 87.00 SGD 108.75 SGD 55
EV/EBIT 7.24 SGD 8.53 SGD 9.82 SGD 66
EV/EBITDA 6.86 SGD 8.02 SGD 9.18 SGD 67
EV/Revenue 5.56 SGD 6.49 SGD 7.43 SGD 54
Asset-Based
NCAV (Graham) 12.28 SGD 18.61 SGD 23.26 SGD 54
Growth DCF
Growth DCF 6.86 SGD 9.65 SGD 14.77 SGD 78
Rev-Margin DCF 5.94 SGD 7.66 SGD 9.85 SGD 74
Economic Profit
Residual Income 15.85 SGD 16.67 SGD 18.11 SGD 76
ROIC Compounder 5.97 SGD 6.44 SGD 6.86 SGD 72
Growth Earnings
Growth-Adj P/E 15.81 SGD 22.59 SGD 29.36 SGD 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 68/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 70
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 78
Does it invest with discipline instead of growing at any price?
Low Volatility 93
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2020: revenue and profit before it include the divested business. Growth is measured afresh from 2020.
Revenue growth 1 year
−6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
Start year 2020 (pandemic)
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+20.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.2%
Dividend (yield on the price)3.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.17.2% vs 7.7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 29%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about +17.2% a year for the price.

Watch H02, get fair value alerts →

Compare HAW PAR CORP LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks

Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 68 · Above median
Fair Value upside +11.5% · Above median
Profitability
Return on equity (12 months) 5.2% · Below median
Return on assets 6.0% · Below median
Net margin (12 months) 104.4% · Top 25%
Operating margin (12 months) 28.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) −8.2% · Bottom 25%
Dividend yield (12 months) 3.1% · Top 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (12 months) 12.3× · Cheapest 25%
P/B 0.66× · Cheapest 25%
P/S (12 months) 12.90× · Priciest 25%
Price / free cash flow 51.5× · Priciest 25%
EV/EBITDA 28.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)49 · sector 20
FUTURE (revenue growth)0 · sector 34
PAST (return on equity)21 · sector 41
HEALTH (low debt)100 · sector 93
DIVIDEND (yield)63 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Bristol-Myers Squibb Company BMY $61.71 $75.91 +23% vs H02
Gilead Sciences, Inc GILD $167.47 $187.75 +12% vs H02
Amgen Inc AMGN $461.26 $507.39 +10% vs H02
AbbVie Inc ABBV $286.00 $259.62 −9% vs H02
Novartis AG NOVN CHF 134.26 CHF 120.96 −10% vs H02
Merck & Co MRK $144.67 $129.26 −11% vs H02
Pfizer Inc PFE $30.00 $24.87 −17% vs H02
Roche Holding RO CHF 401.60 CHF 326.56 −19% vs H02
Johnson & Johnson, JNJ $266.17 $168.85 −37% vs H02
Eli Lilly and Company LLY $1,409 $749.92 −47% vs H02

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HAW PAR CORP LTD: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HAW PAR CORP LTD Fair Value". https://www.fairvalue-calculator.com/stock/H02

Frequently asked questions

Is HAW PAR CORP LTD (H02) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of 14.26 SGD versus a price of 12.79 SGD, about +11% upside (undervalued).
What is the fair value of H02?
Our model-based fair value for HAW PAR CORP LTD is 14.26 SGD (as of Nov 1, 2026), built from audited fundamentals. The current price: 12.79 SGD.
What is the quality score of H02?
HAW PAR CORP LTD has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HAW PAR CORP LTD (H02)?
Our model-based price target is the fair value of 14.26 SGD (as of Nov 1, 2026) from 26 valuation models. Cautious scenario 10.70 SGD, optimistic scenario 21.82 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the HAW PAR CORP LTD stock forecast for 2026?
Our models put fair value at 14.26 SGD, about +11% upside versus a price of 12.79 SGD (undervalued). Cautious scenario 10.70 SGD, optimistic scenario 21.82 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of HAW PAR CORP LTD (H02)?
HAW PAR CORP LTD reported trailing-twelve-month revenue of about 220M SGD (latest available figure, as of Nov 1, 2026).
Does HAW PAR CORP LTD pay a dividend?
HAW PAR CORP LTD currently shows a dividend yield of 3.13% relative to its recent price (as of Nov 1, 2026).
What growth is priced into HAW PAR CORP LTD (H02)?
For today's price to be fair in a discounted-cash-flow model, HAW PAR CORP LTD would have to grow free cash flow by +19.6 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.7 % per year. As of Nov 1, 2026.
What discount rate (WACC) does the fair value of H02 use?
Our models discount HAW PAR CORP LTD at 8.3 %: a base by market capitalisation (mid), damped by beta 0.16, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HAW PAR CORP LTD that is +19.6 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has HAW PAR CORP LTD (H02) delivered so far?
Over the past 5 years revenue at HAW PAR CORP LTD grew +15.7 % a year. The price currently implies +19.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HAW PAR CORP LTD (H02) growing?
The median revenue growth in the sector is +6.3 % a year. That is the yardstick for the growth priced into HAW PAR CORP LTD (+19.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HAW PAR CORP LTD (H02)?
The free-cash-flow yield on the price is 1.94 %: that much free cash flow HAW PAR CORP LTD produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HAW PAR CORP LTD (H02)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HAW PAR CORP LTD it is 14.26 SGD per share (as of Nov 1, 2026), against a price of 12.79 SGD. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is HAW PAR CORP LTD stock overvalued or undervalued in 2026?
As of Nov 1, 2026, H02 trades below its calculated fair value: price 12.79 SGD, fair value 14.26 SGD, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of H02?
No. The price is what the market pays today (12.79 SGD); the fair value is what the company's own numbers justify (14.26 SGD). For HAW PAR CORP LTD the two are 1.47 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is HAW PAR CORP LTD worth?
The market values HAW PAR CORP LTD at about 2.8B SGD (market capitalisation, as of Nov 1, 2026). Per share that is 12.79 SGD; our models calculate a fair value of 14.26 SGD per share.
What do the bullish and bearish scenarios say about H02?
Our models span a range for HAW PAR CORP LTD: cautious scenario 10.70 SGD, base 14.26 SGD, optimistic 21.82 SGD per share (as of Nov 1, 2026, price 12.79 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of H02?
HAW PAR CORP LTD trades at a price-to-earnings ratio of 12.3 (as of Nov 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 14.26 SGD is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 15.2. Other multiples: P/B 0.7, P/S 12.9, EV/EBITDA 28.8.
How solid is the balance sheet of HAW PAR CORP LTD (H02)?
Balance-sheet figures for HAW PAR CORP LTD (as of Nov 1, 2026): return on equity 5.2%, debt of 0.01 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is H02 from its 52-week high?
HAW PAR CORP LTD trades at 12.79 SGD, about 28% below its 52-week high of 17.81 SGD and 1% above the low of 12.70 SGD (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of 14.26 SGD is for.
Which stocks are comparable to HAW PAR CORP LTD?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HAW PAR CORP LTD stock attractive at the current price?
The data as of Nov 1, 2026: price 12.79 SGD, calculated fair value 14.26 SGD (+11%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of H02 calculated?
We run HAW PAR CORP LTD through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 14.26 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. HAW PAR CORP LTD currently trades 10% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HAW PAR CORP LTD (H02)?
The closing price on Nov 4, 2026 was 12.79 SGD. Our model-based fair value is 14.26 SGD, about +11% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HAW PAR CORP LTD right now?
A fairly wide model range (10.70 SGD to 21.82 SGD) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.

Key figures of HAW PAR CORP LTD

How large is the market capitalisation of HAW PAR CORP LTD (H02)?
The market capitalisation of HAW PAR CORP LTD is 2.8B SGD (≈ $2.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HAW PAR CORP LTD (H02)?
The price-to-sales ratio of HAW PAR CORP LTD is 12.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HAW PAR CORP LTD (H02)?
Earnings per share at HAW PAR CORP LTD are 1.04 SGD (price ÷ EPS = P/E 12.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of HAW PAR CORP LTD (H02)?
The dividend yield of HAW PAR CORP LTD is 3.1% (payout 38.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HAW PAR CORP LTD (H02)?
The net margin of HAW PAR CORP LTD is 104% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HAW PAR CORP LTD (H02)?
The return on equity (ROE) of HAW PAR CORP LTD is 5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HAW PAR CORP LTD (H02)?
On an EBIT basis the return on assets of HAW PAR CORP LTD is 1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HAW PAR CORP LTD (H02)?
The operating margin of HAW PAR CORP LTD is 28.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HAW PAR CORP LTD (H02)?
Revenue at HAW PAR CORP LTD is growing −8.2% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HAW PAR CORP LTD (H02)?
Earnings per share at HAW PAR CORP LTD are growing −25.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch HAW PAR CORP LTD in the live analysis

One click puts HAW PAR CORP LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.